Companion files · The Private Markets Career Guides

The Life Science Real Estate Investor

Underwriting Lab and R&D Buildings: Biotech Tenant Credit, Tenant Improvements, Office-to-Lab Conversion, Development and the 2021 to 2026 Cycle.

These are the companion files of the book. One workbook rebuilds the Corlund Science Center, the fictional lab building of the case: 150,000 RSF, three tenants and a vacant suite, studied by Quaywright Life Science Fund I at $140.00 million. It follows the rent roll and the biotech's credit, every lease the plan assumes, the operating costs, the cash flow from 2027 to 2031, the loan and its cash management test, the returns and the downside cases, then the conversion of the Evenmoor office building and a new development on the Thornell site. A toolkit holds the checklists of Appendix B in an editable form.

The workbook, the toolkit and the read-me, in one archive134 KB

The archive holds the workbook, the toolkit and 00_START_HERE.md. No macros, no circular references, no external links. The workbook recalculates in Excel, LibreOffice or Google Sheets.

The files

Three numbers to reproduce first

The net effective rentA new lease on the vacant suite at $74.16 per RSF nets $62.60 per RSF a year once free rent, TI of $150.00 per RSF and the commission are spread over its ten years
The price$140.00 million, a going-in yield of 6.56 percent; unlevered IRR 9.97 percent, levered 13.64 percent and 1.82x on the equity
The alternativesConverting Evenmoor yields 5.84 percent on cost and building on Thornell 6.71 percent, against an exit yield of 6.75 percent

The files are provided as they are, without warranty of any kind. The model is illustrative: Quaywright Real Estate Partners, its Fund, the Corlund Science Center, the Evenmoor building, the Thornell site and the three tenants are fictional, and rents, costs, prices, yields, rates and dates are the book’s assumptions, not the terms of any real building, tenant or lender, the quote of any real market or a forecast. Nothing here is legal, tax, engineering or investment advice.